Pharma in Silica
Pharma in silica is developing a proprietary silica nanocarrier technology aimed at creating precise, well-tolerated chemotherapy treatments that improve outcomes and reduce side effects for cancer patients. The company focuses on early-stage product development, platform innovation, and strategic partnerships to revolutionize oncology treatments.
Industries
Nr. of Employees
small (1-50)
Pharma in Silica
Quebec, Quebec, Canada, North America
Products
OpPacli (paclitaxel-loaded silica nanoparticle candidate for NSCLC)
Paclitaxel sequestered in ~40 nm biocompatible silica nanoparticles produced via a surfactant-free process; saline injectable formulation with tumor-triggered release designed for reduced systemic toxicity and increased tumor delivery; planned IND-enabling activities and Phase Ib/IIa clinical study.
ImPacli (metronomic paclitaxel prototype)
In-house proof-of-concept program applying metronomic dosing of paclitaxel delivered via silica nanocarrier to enhance immune response in solid tumors.
OpCombo (synchronized multi-compound release prototype)
In-house program for multi-compound formulations with synchronized release kinetics for oncology or hepatic indications.
OpKinib (in-licensed kinase inhibitor controlled-release prototype)
Program to formulate an in-licensed kinase inhibitor into a controlled-release silica nanocarrier for solid tumors.
OpPacli (paclitaxel-loaded silica nanoparticle candidate for NSCLC)
Paclitaxel sequestered in ~40 nm biocompatible silica nanoparticles produced via a surfactant-free process; saline injectable formulation with tumor-triggered release designed for reduced systemic toxicity and increased tumor delivery; planned IND-enabling activities and Phase Ib/IIa clinical study.
ImPacli (metronomic paclitaxel prototype)
In-house proof-of-concept program applying metronomic dosing of paclitaxel delivered via silica nanocarrier to enhance immune response in solid tumors.
OpCombo (synchronized multi-compound release prototype)
In-house program for multi-compound formulations with synchronized release kinetics for oncology or hepatic indications.
OpKinib (in-licensed kinase inhibitor controlled-release prototype)
Program to formulate an in-licensed kinase inhibitor into a controlled-release silica nanocarrier for solid tumors.
Services
Preclinical and IND-enabling studies
Design and execution of preclinical packages, toxicology, PK/PD and study plans compliant with pre-IND / pre-CTA interactions to support IND submissions.
CMC development and clinical-grade manufacturing support
CMC development, scale-up and preparation for clinical-grade (FDA-compliant) production of cytotoxic-loaded nanoparticles and associated process development.
Platform integration and add-on development
Integration of third-party targeting ligands, imaging labels and functional modules into a modular silica nanocarrier platform via codevelopment, licensing or acquisition.
Business development and partnering advisory
Preparation of asset-specific value propositions, market analyses and tailored partnering proposals; negotiation support for licensing, supply and co-development agreements.
Preclinical and IND-enabling studies
Design and execution of preclinical packages, toxicology, PK/PD and study plans compliant with pre-IND / pre-CTA interactions to support IND submissions.
CMC development and clinical-grade manufacturing support
CMC development, scale-up and preparation for clinical-grade (FDA-compliant) production of cytotoxic-loaded nanoparticles and associated process development.
Platform integration and add-on development
Integration of third-party targeting ligands, imaging labels and functional modules into a modular silica nanocarrier platform via codevelopment, licensing or acquisition.
Business development and partnering advisory
Preparation of asset-specific value propositions, market analyses and tailored partnering proposals; negotiation support for licensing, supply and co-development agreements.
Expertise Areas
- Nanoparticle formulation and silica chemistry
- Drug encapsulation and controlled-release formulation
- CMC development and clinical-grade manufacturing
- Preclinical safety and toxicology assessment
Key Technologies
- Silica nanoparticle carriers
- Porous-matrix drug encapsulation
- Stimuli-responsive (tumor-triggered) release
- Surface functionalization for stealth and solubility